Metraipolis › archive › dc_fe78e7055173

BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis — Europe PMC PMID:41464754

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41464754
DOI
10.3390/jcm14248854
License (as archived)
solo-consultazione
Archived
2026-11-07T16:01:17.938Z
SHA-256 of the archived text
a54c48527d6c96c8fbbf4962aa7368c4826ccacd32c3a0c42f4829ddf22ddd9f
Stable URL of this page
https://metraipolis.com/documento/dc_fe78e7055173

How to cite

BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis — Europe PMC PMID:41464754 — Europe PMC (en), https://europepmc.org/article/MED/41464754 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe78e7055173 (Metraipolis archive dc_fe78e7055173, sha256 a54c48527d6c96c8fbbf4962aa7368c4826ccacd32c3a0c42f4829ddf22ddd9f)
BibTeX
@misc{dcfe78e7055173,
  title = {BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis — Europe PMC PMID:41464754},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41464754},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe78e7055173; sha256 a54c48527d6c96c8fbbf4962aa7368c4826ccacd32c3a0c42f4829ddf22ddd9f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41464754. Agents can read the archived copy with the MCP tool read_document.